Production of Clotting Factors Through Biotechnology

  • L.-O. Andersson
Part of the Developments in Hematology and Immunology book series (DIHI, volume 21)


Fractionation of plasma is a way to prepare a number of proteins for clinical use, of great value in treatment and prevention of a number of diseases and disease states. Of special importance are the coagulation factor concentrates used for treatment of hemophilia. In treatment of hemophilia A Factor VIII concentrates are used and for treatment of hemophilia B Factor IX concentrates. Before those concentrates were developed there was essentially no treatment for hemophilia patients and life-expectancy was poor. Average lifespan was around 16 years. With the introduction of the Factor VIII and IX concentrates in the 60ties life has completely changed for hemophilia patients. They now can live an almost normal life.


Factor VIII Hemophilia Patient Factor Viii Gene Human Factor VIII Plasma Factor VIII 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Choo KH, Gould KJ, Rees DJG, Brownlee GG. Molecular cloning of the gene for human antihaemophiliac Factor IX. Nature 1982;299:178–80.PubMedCrossRefGoogle Scholar
  2. 2.
    Kurachi K, Davie EW. Isolation and characterization of a CDNA coding for human Factor IX. Proc Natl Acad Sci (USA) 1982;79:6461–4.CrossRefGoogle Scholar
  3. 3.
    De la Salle H, Altenburger W, Elkaim R et al. Active7 -carboxylated human Factor IX expressed using recombinant DNA techniques. Nature 1985;316: 268–70.PubMedCrossRefGoogle Scholar
  4. 4.
    Busby S, Kumar A, Joseph M et al. Expression of active human Factor IX in transfected cells. Nature 1985;316:271–3.PubMedCrossRefGoogle Scholar
  5. 5.
    Rotblat F, O’Brien D.P, O’Brien FJ, Goodall AH, Tuddenham EGD. Purification of human Factor VIII:C and characterization by western blotting using monoclonal antibodies. Biochemistry 1985;24:4294–300.PubMedCrossRefGoogle Scholar
  6. 6.
    Andersson L-O, Forsman N, Huang K et al. Isolation and characterization of human Factor VIII: Molecular forms in commercial Factor VIII concentrate, cryoprecipitate and plasma. Proc Natl Acad Sci (USA) 1986;83:2979–83.CrossRefGoogle Scholar
  7. 7.
    Gitschier J, Wood WI, Goralka TM et al. Characterization of the human Factor VIII gene. Nature 1984;312:326–30.PubMedCrossRefGoogle Scholar
  8. 8.
    Toole JJ, Knopf JL, Wozney JM et al. Molecular cloning of a CDNA encoding human antihemophilic factor. Nature 1984;312:342–7.PubMedCrossRefGoogle Scholar
  9. 9.
    High KA, White II GC, McMillan CW, Macik BG, Roberts HR. In vivo characteristics of rDNA F VIII: The impact for the future in hemophilia care. In: Smit Sibinga CTh, Das C, Overby LR (eds). Biotechnology in blood transfusion. Martinus Nijhoff Publ: Boston/Dordrecht/Lancaster 1988:223–230.Google Scholar

Copyright information

© Kluwer Academic Publishers, Boston 1988

Authors and Affiliations

  • L.-O. Andersson

There are no affiliations available

Personalised recommendations